Drug intelligence / Profile preview

PH3

Development stage: Phase 2
Lead developer: PhytoHealth
Modality: Small Molecules
Administration: Oral

Overview

PH3 is an investigational drug developed by PhytoHealth Corporation. It is being evaluated in clinical trials for its effectiveness and safety in treating diabetic nephropathy and for the prevention of osteoporosis in postmenopausal women. The drug is formulated as a 530 mg tablet containing 250 mg of active ingredient and is administered orally. The specific mechanism of action for PH3 has not been disclosed in the provided context.

Beyond the preview

Go deeper on PH3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PH3.

Explore the full profile